In recent months, CMI began redirecting many of its efforts to better understand how the human microbiome is involved in the development and severity of COVID-19.
Researchers have since been evaluating samples from patients worldwide to find biological and epidemiological discoveries about the SARS-CoV-2 virus.
CMI director Rob Knight also noted the importance of a reliable HPC technology solution as the Center steps up its groundbreaking efforts to study the RNA microbiome, which is especially relevant because COVID-19 is an RNA virus.
CMI has been working with Panasas since 2015, when they were looking to create an HPC storage infrastructure that could deliver consistently high performance, speed data exploration and discovery, and simplify storage management for administrators.
The CMI team appreciates technology solutions that don't distract researchers from the scientific problems they aspire to solve. By freeing researchers from worries about storage, CMI can accelerate the adoption of advanced scientific technologies.
ActiveStor is a turnkey HPC storage appliance that runs the PanFS parallel file system to accelerate performance at every stage of the computational research process.
It delivers unlimited performance scaling and features a balanced node architecture that prevents hot spots and bottlenecks by automatically adapting to dynamically changing workloads and increasing demands - all at the industry's lowest total cost of ownership.
Panasas delivers high-performance computing data storage solutions that support industry and research innovation around the world.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial